{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:56:23Z","timestamp":1790657783798,"version":"4.1.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s13300-026-01913-0","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:30:28Z","timestamp":1787988628000},"page":"1435-1448","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Role of SGLT2 Inhibitors in the Prevention of Type 2 Diabetes: A Narrative Review of Current Evidence"],"prefix":"10.1007","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5021-446X","authenticated-orcid":false,"given":"Anna C.","family":"Owczarczyk-Durma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6636-7863","authenticated-orcid":false,"given":"Monika","family":"Blicharska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2396-8885","authenticated-orcid":false,"given":"Leszek","family":"Czupryniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,29]]},"reference":[{"key":"1913_CR1","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee. 2. Diagnosis and classification of diabetes: standards of care in diabetes\u20142026. Diabetes Care. 2026;49(Suppl 1):S27\u2013S49.","DOI":"10.2337\/dc26-S002"},{"issue":"2","key":"1913_CR2","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S2213-8587(25)00299-2","volume":"14","author":"I Genitsaridi","year":"2024","unstructured":"Genitsaridi I, Salpea P, Salim A, et al. 11th edition of the IDF Diabetes Atlas: global, regional, and national diabetes prevalence estimates for 2024 and projections for 2050. Lancet Diabetes Endocrinol. 2024;14(2):149\u201356.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"1913_CR3","doi-asserted-by":"publisher","first-page":"e142","DOI":"10.2337\/dc25-1640","volume":"48","author":"MR Rooney","year":"2024","unstructured":"Rooney MR, He JH, Salpea P, et al. Global and regional prediabetes prevalence: updates for 2024 and projections for 2050. Diabetes Care. 2024;48(11):e142\u20134.","journal-title":"Diabetes Care"},{"issue":"3","key":"1913_CR4","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.diabres.2007.05.004","volume":"78","author":"HC Gerstein","year":"2007","unstructured":"Gerstein HC, Santaguida P, Raina P, et al. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. Diabetes Res Clin Pract. 2007;78(3):305\u201312.","journal-title":"Diabetes Res Clin Pract"},{"issue":"9833","key":"1913_CR5","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1016\/S0140-6736(12)60283-9","volume":"379","author":"AG Tab\u00e1k","year":"2012","unstructured":"Tab\u00e1k AG, Herder C, Rathmann W, Brunner EJ, Kivim\u00e4ki M. Prediabetes: a high-risk state for diabetes development. Lancet. 2012;379(9833):2279\u201390.","journal-title":"Lancet"},{"key":"1913_CR6","doi-asserted-by":"publisher","first-page":"7839101","DOI":"10.1155\/2017\/7839101","volume":"2017","author":"D Huang","year":"2017","unstructured":"Huang D, Refaat M, Mohammedi K, Jayyousi A, Al Suwaidi J, Abi KC. Macrovascular complications in patients with diabetes and prediabetes. Biomed Res Int. 2017;2017:7839101.","journal-title":"Biomed Res Int"},{"issue":"4","key":"1913_CR7","doi-asserted-by":"publisher","first-page":"289","DOI":"10.14797\/mdcj-14-4-289","volume":"14","author":"A Zand","year":"2018","unstructured":"Zand A, Ibrahim K, Patham B. Prediabetes: why should we care? Methodist Debakey Cardiovasc J. 2018;14(4):289\u201397.","journal-title":"Methodist Debakey Cardiovasc J"},{"key":"1913_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i5953","volume":"355","author":"Y Huang","year":"2016","unstructured":"Huang Y, Cai X, Mai W, Li M, Hu Y. Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis. BMJ. 2016;355:i5953.","journal-title":"BMJ"},{"issue":"12","key":"1913_CR9","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.2337\/diacare.25.12.2165","volume":"25","author":"Diabetes Prevention Program (DPP) Research Group","year":"2002","unstructured":"Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care. 2002;25(12):2165\u201371.","journal-title":"Diabetes Care"},{"issue":"6","key":"1913_CR10","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa012512","volume":"346","author":"WC Knowler","year":"2002","unstructured":"Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393\u2013403.","journal-title":"N Engl J Med"},{"issue":"12","key":"1913_CR11","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1056\/NEJMoa1010949","volume":"364","author":"RA DeFronzo","year":"2011","unstructured":"DeFronzo RA, Tripathy D, Schwenke DC, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011;364(12):1104\u201315.","journal-title":"N Engl J Med"},{"issue":"9323","key":"1913_CR12","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1016\/S0140-6736(02)08905-5","volume":"359","author":"JL Chiasson","year":"2002","unstructured":"Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359(9323):2072\u20137. https:\/\/doi.org\/10.1016\/S0140-6736(02)08905-5.","journal-title":"Lancet"},{"issue":"10077","key":"1913_CR13","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","volume":"389","author":"CW le Roux","year":"2017","unstructured":"le Roux CW, Astrup A, Fujioka K, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017;389(10077):1399\u2013409.","journal-title":"Lancet"},{"issue":"11","key":"1913_CR14","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989\u20131002.","journal-title":"N Engl J Med"},{"issue":"3","key":"1913_CR15","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205\u201316.","journal-title":"N Engl J Med"},{"issue":"16","key":"1913_CR16","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451\u201361.","journal-title":"N Engl J Med"},{"issue":"15","key":"1913_CR17","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346.","journal-title":"N Engl J Med"},{"key":"1913_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1118848","volume":"14","author":"P Majety","year":"2023","unstructured":"Majety P, Lozada Orquera FA, Edem D, Hamdy O. Pharmacological approaches to the prevention of type 2 diabetes mellitus. Front Endocrinol. 2023;14:1118848.","journal-title":"Front Endocrinol"},{"issue":"1","key":"1913_CR19","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1210\/clinem\/dgac591","volume":"108","author":"Y Mori","year":"2023","unstructured":"Mori Y, Duru OK, Tuttle KR, et al. Sodium-glucose cotransporter 2 inhibitors and new-onset type 2 diabetes in adults with prediabetes: systematic review and meta-analysis of randomized controlled trials. J Clin Endocrinol Metab. 2023;108(1):221\u201331.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1913_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2023.102789","volume":"17","author":"AK Singh","year":"2023","unstructured":"Singh AK, Singh A, Singh R. New-onset diabetes with sodium-glucose cotransporter-2 inhibitors in prediabetes: an updated meta-analysis and possible mechanisms. Diabetes Metab Syndr. 2023;17(6):102789.","journal-title":"Diabetes Metab Syndr"},{"issue":"2","key":"1913_CR21","doi-asserted-by":"publisher","first-page":"586","DOI":"10.2337\/dc20-1675","volume":"44","author":"SE Inzucchi","year":"2021","unstructured":"Inzucchi SE, Docherty KF, K\u00f8ber L, et al. Dapagliflozin and the incidence of type 2 diabetes in patients with heart failure and reduced ejection fraction: an exploratory analysis from DAPA-HF. Diabetes Care. 2021;44(2):586\u201394.","journal-title":"Diabetes Care"},{"issue":"8","key":"1913_CR22","volume":"14","author":"MF Hossain","year":"2022","unstructured":"Hossain MF, Khan NA, Rahman A, et al. Empagliflozin ameliorates progression from prediabetes to diabetes and improves hepatic lipid metabolism: a systematic review. Cureus. 2022;14(8):e28367.","journal-title":"Cureus"},{"issue":"4","key":"1913_CR23","doi-asserted-by":"publisher","first-page":"681","DOI":"10.2337\/db19-0770","volume":"69","author":"M Alatrach","year":"2020","unstructured":"Alatrach M, Laichuthai N, Martinez R, et al. Evidence against an important role of plasma insulin and glucagon concentrations in the increase in EGP caused by SGLT2 inhibitors. Diabetes. 2020;69(4):681\u20138.","journal-title":"Diabetes"},{"issue":"2","key":"1913_CR24","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1172\/JCI72227","volume":"124","author":"E Ferrannini","year":"2014","unstructured":"Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124(2):499\u2013508.","journal-title":"J Clin Invest"},{"issue":"2","key":"1913_CR25","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1172\/JCI70704","volume":"124","author":"A Merovci","year":"2014","unstructured":"Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Investig. 2014;124(2):509\u201314.","journal-title":"J Clin Investig"},{"issue":"11","key":"1913_CR26","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.2337\/dc15-2688","volume":"39","author":"G Daniele","year":"2016","unstructured":"Daniele G, Xiong J, Solis-Herrera C, et al. Dapagliflozin enhances fat oxidation and ketone production in patients with type 2 diabetes. Diabetes Care. 2016;39(11):2036\u201341.","journal-title":"Diabetes Care"},{"issue":"7","key":"1913_CR27","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.2337\/dc11-1693","volume":"35","author":"J Rosenstock","year":"2012","unstructured":"Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care. 2012;35(7):1473\u20138.","journal-title":"Diabetes Care"},{"key":"1913_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2022.155396","volume":"140","author":"A Veelen","year":"2023","unstructured":"Veelen A, Andriessen C, Op den Kamp Y, et al. Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on substrate metabolism in prediabetic insulin resistant individuals: a randomized, double-blind crossover trial. Metabolism. 2023;140:155396.","journal-title":"Metabolism"},{"issue":"6","key":"1913_CR29","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.004007","volume":"6","author":"M Mazidi","year":"2017","unstructured":"Mazidi M, Rezaie P, Gao HK, Kengne AP. Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22 528 patients. J Am Heart Assoc. 2017;6(6):e004007.","journal-title":"J Am Heart Assoc"},{"issue":"7","key":"1913_CR30","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"22","key":"1913_CR31","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"6","key":"1913_CR32","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","volume":"5","author":"GD Lopaschuk","year":"2020","unstructured":"Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review. JACC Basic Transl Sci. 2020;5(6):632\u201344.","journal-title":"JACC Basic Transl Sci"},{"key":"1913_CR33","first-page":"11","volume":"435","author":"L Mayans","year":"2015","unstructured":"Mayans L. Metabolic syndrome: insulin resistance and prediabetes. FP Essent. 2015;435:11\u20136.","journal-title":"FP Essent"},{"issue":"1","key":"1913_CR34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4093\/dmj.2021.0280","volume":"46","author":"SH Lee","year":"2022","unstructured":"Lee SH, Park SY, Choi CS. Insulin resistance: from mechanisms to therapeutic strategies. Diabetes Metab J. 2022;46(1):15\u201337. https:\/\/doi.org\/10.4093\/dmj.2021.0280.","journal-title":"Diabetes Metab J"},{"issue":"2","key":"1913_CR35","doi-asserted-by":"publisher","first-page":"398","DOI":"10.2337\/dc21-1136","volume":"45","author":"S Kullmann","year":"2022","unstructured":"Kullmann S, Hummel J, Wagner R, et al. Empagliflozin improves insulin sensitivity of the hypothalamus in humans with prediabetes: a randomized, double-blind, placebo-controlled, phase 2 trial. Diabetes Care. 2022;45(2):398\u2013406.","journal-title":"Diabetes Care"},{"issue":"8","key":"1913_CR36","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1055\/a-0664-7583","volume":"128","author":"AM Ram\u00edrez-Rodr\u00edguez","year":"2020","unstructured":"Ram\u00edrez-Rodr\u00edguez AM, Gonz\u00e1lez-Ortiz M, Mart\u00ednez-Abundis E. Effect of dapagliflozin on insulin secretion and insulin sensitivity in patients with prediabetes. Exp Clin Endocrinol Diabetes. 2020;128(8):506\u201311.","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"2","key":"1913_CR37","doi-asserted-by":"publisher","first-page":"97","DOI":"10.5455\/medarh.2023.77.97-104","volume":"77","author":"V Cosic","year":"2023","unstructured":"Cosic V, Jakab J, Pravecek MK, Miskic B. The importance of prediabetes screening in the prevention of cardiovascular disease. Med Arch. 2023;77(2):97\u2013104.","journal-title":"Med Arch"},{"issue":"1","key":"1913_CR38","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12933-019-0820-6","volume":"18","author":"DD Adingupu","year":"2019","unstructured":"Adingupu DD, G\u00f6pel SO, Gr\u00f6nros J, et al. SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob\/ob\u2212\/\u2212 mice. Cardiovasc Diabetol. 2019;18(1):16.","journal-title":"Cardiovasc Diabetol"},{"issue":"12","key":"1913_CR39","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089\u201398.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"1913_CR40","doi-asserted-by":"publisher","first-page":"S50","DOI":"10.2337\/dc26-S003","volume":"49","author":"American Diabetes Association Professional Practice Committee","year":"2026","unstructured":"American Diabetes Association Professional Practice Committee. 3. Prevention or delay of diabetes and associated comorbidities; 10. Cardiovascular disease and risk management: standards of care in diabetes\u20142026. Diabetes Care. 2026;49(Suppl 1):S50\u2013216.","journal-title":"Diabetes Care"},{"issue":"2","key":"1913_CR41","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"WG Herrington","year":"2023","unstructured":"The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117\u201327.","journal-title":"N Engl J Med"},{"issue":"3","key":"1913_CR42","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1001\/jama.2025.20834","volume":"335","author":"BL Neuen","year":"2026","unstructured":"Neuen BL, Fletcher RA, Anker SD, et al. SGLT2 inhibitors and kidney outcomes by glomerular filtration rate and albuminuria: a meta-analysis. JAMA. 2026;335(3):233\u201344. https:\/\/doi.org\/10.1001\/jama.2025.20834.","journal-title":"JAMA"},{"issue":"Suppl 1","key":"1913_CR43","doi-asserted-by":"publisher","first-page":"S246","DOI":"10.2337\/dc26-S011","volume":"49","author":"American Diabetes Association Professional Practice Committee for Diabetes","year":"2026","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes. 11. Chronic kidney disease and risk management: standards of care in diabetes\u20142026. Diabetes Care. 2026;49(Suppl 1):S246\u201360. https:\/\/doi.org\/10.2337\/dc26-S011.","journal-title":"Diabetes Care"},{"issue":"6","key":"1913_CR44","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966\u201386.","journal-title":"Hepatology"},{"key":"1913_CR45","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/5584_2020_479","volume":"1307","author":"MS Kuchay","year":"2021","unstructured":"Kuchay MS, Farooqui KJ, Mishra SK, Mithal A. Glucose lowering efficacy and pleiotropic effects of sodium-glucose cotransporter 2 inhibitors. Adv Exp Med Biol. 2021;1307:213\u201330.","journal-title":"Adv Exp Med Biol"},{"issue":"3","key":"1913_CR46","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s13300-021-01011-3","volume":"12","author":"H Chehrehgosha","year":"2021","unstructured":"Chehrehgosha H, Sohrabi MR, Ismail-Beigi F, et al. Empagliflozin improves liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial. Diabetes Ther. 2021;12(3):843\u201361.","journal-title":"Diabetes Ther"},{"issue":"11","key":"1913_CR47","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1007\/s12325-020-01498-5","volume":"37","author":"H Taheri","year":"2020","unstructured":"Taheri H, Malek M, Ismail-Beigi F, et al. Effect of empagliflozin on liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease without diabetes: a randomized, double-blind, placebo-controlled trial. Adv Ther. 2020;37(11):4697\u2013708.","journal-title":"Adv Ther"},{"issue":"21","key":"1913_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222111513","volume":"22","author":"M H\u00fcttl","year":"2021","unstructured":"H\u00fcttl M, Markova I, Miklankova D, et al. In a prediabetic model, empagliflozin improves hepatic lipid metabolism independently of obesity and before onset of hyperglycemia. Int J Mol Sci. 2021;22(21):11513.","journal-title":"Int J Mol Sci"},{"key":"1913_CR49","doi-asserted-by":"publisher","first-page":"1667823","DOI":"10.3389\/fmed.2025.1667823","volume":"12","author":"L Yang","year":"2025","unstructured":"Yang L, Ruan J, Fang Y, Xu A. Effect of SGLT-2 inhibitors on liver fibrosis progression in patients with MASLD: an updated meta-analysis based on RCTs. Front Med. 2025;12:1667823.","journal-title":"Front Med"},{"issue":"8","key":"1913_CR50","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.3390\/ph18081118","volume":"18","author":"M Suki","year":"2025","unstructured":"Suki M, Imam A, Amer J, et al. SGLT2 inhibitors in MASLD (metabolic dysfunction-associated steatotic liver disease) associated with sustained hepatic benefits, besides the cardiometabolic. Pharmaceuticals. 2025;18(8):1118.","journal-title":"Pharmaceuticals"},{"issue":"2","key":"1913_CR51","doi-asserted-by":"publisher","DOI":"10.1007\/s40200-025-01797-0","volume":"24","author":"MS Abbas","year":"2025","unstructured":"Abbas MS, Dandamudi M, Rehman T, et al. Efficacy of SGLT2 inhibitors in non-diabetic non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Diabetes Metab Disord. 2025;24(2):285. https:\/\/doi.org\/10.1007\/s40200-025-01797-0.","journal-title":"J Diabetes Metab Disord"},{"issue":"4","key":"1913_CR52","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1161\/CIRCULATIONAHA.120.051824","volume":"143","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, et al. Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status: results from the EMPEROR-Reduced trial. Circulation. 2021;143(4):337\u201349.","journal-title":"Circulation"},{"issue":"9","key":"1913_CR53","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1161\/CIRCULATIONAHA.122.059785","volume":"146","author":"G Filippatos","year":"2022","unstructured":"Filippatos G, Butler J, Farmakis D, et al. Empagliflozin for heart failure with preserved left ventricular ejection fraction with and without diabetes. Circulation. 2022;146(9):676\u201386.","journal-title":"Circulation"},{"issue":"1","key":"1913_CR54","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s00125-020-05306-1","volume":"64","author":"K F\u00e6rch","year":"2021","unstructured":"F\u00e6rch K, Blond MB, Bruhn L, et al. The effects of dapagliflozin, metformin or exercise on glycaemic variability in overweight or obese individuals with prediabetes (the PRE-D trial): a multi-arm, randomised, controlled trial. Diabetologia. 2021;64(1):42\u201355.","journal-title":"Diabetologia"},{"key":"1913_CR55","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae780","author":"JW Ostrominski","year":"2025","unstructured":"Ostrominski JW, H\u00f8jbjerg Lassen MC, Claggett BL, et al. Sodium-glucose co-transporter 2 inhibitors and new-onset diabetes in cardiovascular or kidney disease. Eur Heart J. 2025. https:\/\/doi.org\/10.1093\/eurheartj\/ehae780.","journal-title":"Eur Heart J"},{"issue":"8","key":"1913_CR56","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1001\/jama.2016.11237","volume":"316","author":"AS Kesselheim","year":"2016","unstructured":"Kesselheim AS, Avorn J, Sarpatwari A. The high cost of prescription drugs in the United States: origins and prospects for reform. JAMA. 2016;316(8):858\u201371.","journal-title":"JAMA"},{"issue":"12","key":"1913_CR57","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1111\/dom.14162","volume":"22","author":"P McEwan","year":"2020","unstructured":"McEwan P, Bennett H, Khunti K, et al. Assessing the cost-effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus: a comprehensive economic evaluation using clinical trial and real-world evidence. Diabetes Obes Metab. 2020;22(12):2364\u201374. https:\/\/doi.org\/10.1111\/dom.14162.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"1913_CR58","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1007\/s00125-022-05832-0","volume":"66","author":"JI Morton","year":"2023","unstructured":"Morton JI, Marquina C, Shaw JE, et al. Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: a cost-effectiveness analysis. Diabetologia. 2023;66(4):642\u201356. https:\/\/doi.org\/10.1007\/s00125-022-05832-0.","journal-title":"Diabetologia"},{"issue":"15","key":"1913_CR59","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413\u201324.","journal-title":"N Engl J Med"},{"issue":"21","key":"1913_CR60","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008.","journal-title":"N Engl J Med"},{"issue":"15","key":"1913_CR61","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","volume":"383","author":"CP Cannon","year":"2020","unstructured":"Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383(15):1425\u201335.","journal-title":"N Engl J Med"},{"issue":"12","key":"1913_CR62","doi-asserted-by":"publisher","DOI":"10.3390\/medicines9120059","volume":"9","author":"S Uitrakul","year":"2022","unstructured":"Uitrakul S, Aksonnam K, Srivichai P, Wicheannarat S, Incomenoy S. The incidence and risk factors of urinary tract infection in patients with type 2 diabetes mellitus using SGLT2 inhibitors: a real-world observational study. Medicines. 2022;9(12):59.","journal-title":"Medicines"},{"issue":"4","key":"1913_CR63","doi-asserted-by":"publisher","first-page":"248","DOI":"10.7326\/M18-3136","volume":"171","author":"CV Dave","year":"2019","unstructured":"Dave CV, Schneeweiss S, Kim D, Fralick M, Tong A, Patorno E. Sodium-glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections: a population-based cohort study. Ann Intern Med. 2019;171(4):248\u201356.","journal-title":"Ann Intern Med"},{"issue":"9","key":"1913_CR64","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.2337\/dc15-1380","volume":"38","author":"J Rosenstock","year":"2015","unstructured":"Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care. 2015;38(9):1638\u201342.","journal-title":"Diabetes Care"},{"issue":"11","key":"1913_CR65","doi-asserted-by":"publisher","DOI":"10.1097\/MS9.0000000000003890","volume":"87","author":"E Ali","year":"2025","unstructured":"Ali E, Kamran S, Cheema AAA. SGLT2 inhibitors and the underrecognized risk of euglycemic diabetic ketoacidosis: a clinical call for vigilance. Ann Med Surg. 2025;87(11):e3890.","journal-title":"Ann Med Surg"},{"key":"1913_CR66","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k4365","volume":"363","author":"P Ueda","year":"2018","unstructured":"Ueda P, Svanstr\u00f6m H, Melbye M, et al. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ. 2018;363:k4365.","journal-title":"BMJ"},{"issue":"2","key":"1913_CR67","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.amjmed.2007.09.016","volume":"121","author":"SR Salpeter","year":"2008","unstructured":"Salpeter SR, Buckley NS, Kahn JA, Salpeter EE. Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. Am J Med. 2008;121(2):149\u201357. https:\/\/doi.org\/10.1016\/j.amjmed.2007.09.016.","journal-title":"Am J Med"},{"issue":"15","key":"1913_CR68","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346. https:\/\/doi.org\/10.1056\/NEJMoa2024816.","journal-title":"N Engl J Med"},{"issue":"3","key":"1913_CR69","doi-asserted-by":"publisher","first-page":"e202321","DOI":"10.21542\/gcsp.2023.21","volume":"2023","author":"K Samaan","year":"2023","unstructured":"Samaan K, Wagdy K. DELIVER: extending the benefits of SGLT-2 inhibitors. Glob Cardiol Sci Pract. 2023;2023(3):e202321. https:\/\/doi.org\/10.21542\/gcsp.2023.21.","journal-title":"Glob Cardiol Sci Pract"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-026-01913-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-026-01913-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-026-01913-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:18:19Z","timestamp":1790655499000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-026-01913-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,29]]},"references-count":69,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1913"],"URL":"https:\/\/doi.org\/10.1007\/s13300-026-01913-0","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,29]]},"assertion":[{"value":"26 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Anna C. Owczarczyk-Durma, Monika Blicharska and Leszek Czupryniak have nothing to disclose.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}